iBio (IBIO) Short-Term Debt issuances (2023 - 2025)
iBio (IBIO) posted quarterly Short-Term Debt issuances of $105000.0 for Q3 2025, up 115.2% quarter-over-quarter from -$691000.0 in Q2 2024.
iBio (IBIO) Short-Term Debt issuances (2023 - 2025) Analysis & Trends
iBio (IBIO) has reported Short-Term Debt issuances for 3 consecutive years, with $105000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Short-Term Debt issuances changed N/A year-over-year to $105000.0; the TTM figure through Sep 2025 stood at $105000.0 (changed N/A YoY), while the FY2024 annual figure was $204000.0, changed N/A from the prior year.
- Short-Term Debt issuances climbed to $105000.0 in Q3 2025 per IBIO's latest filing, from -$691000.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $691000.0 in Q1 2024 and bottomed at -$691000.0 in Q2 2024.
- Historically, Short-Term Debt issuances has averaged $77250.0 across 3 years, with a median of $154500.0 in 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 105,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Jun 30, 2024 | -691,000.00 |
| Jun 30, 2024 | -691,000.00 |
| Mar 31, 2024 | 691,000.00 |
| Mar 31, 2024 | 691,000.00 |
| Sep 30, 2023 | 204,000.00 |
| Sep 30, 2023 | 204,000.00 |